Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial

Gael B. Morrow; Timea Feller; Zoe McQuilten; Elizabeth Wake; Robert A. S. Ariëns; James Winearls; Nicola J. Mutch; Mike A. Laffan; Nicola  Curry

doi:10.1186/s13054-022-04167-x

Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial

Gael B. Morrow^* (Corresponding Author), Timea Feller, Zoe McQuilten, Elizabeth Wake, Robert A. S. Ariëns, James Winearls, Nicola J. Mutch, Mike A. Laffan, Nicola Curry

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Fibrinogen is the first coagulation protein to reach critical levels during traumatic haemorrhage. This laboratory study compares paired plasma samples pre- and post-fibrinogen replacement from the Fibrinogen Early In Severe Trauma studY (FEISTY; NCT02745041). FEISTY is the first randomised controlled trial to compare the time to administration of cryoprecipitate (cryo) and fibrinogen concentrate (Fg-C; Riastap) in trauma patients. This study will determine differences in clot strength and fibrinolytic stability within individuals and between treatment arms.

Original language	English
Article number	290
Number of pages	12
Journal	Critical Care
Volume	26
Issue number	1
DOIs	https://doi.org/10.1186/s13054-022-04167-x
Publication status	Published - 26 Sep 2022

Keywords

Fibrinogen
cryoprecipitate
clot structure
Trauma coagulopathy
fibrinolysis

Access to Document

10.1186/s13054-022-04167-xLicence: CC BY

Morrow_etal_CC_Cryoprecipitate_transfusion_in_VOR
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.
Final published version, 2.26 MBLicence: CC BY

Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial
Morrow, G. (Creator), Feller, T. (Creator), McQuilten, Z. (Creator), Wake, E. (Creator), Ariëns, R. A. S. (Creator), Winearls, J. (Creator), Mutch, N. (Creator), Laffan, M. A. (Creator) & Curry, N. (Creator), Figshare, 2022
DOI: 10.6084/m9.figshare.c.6218372, https://springernature.figshare.com/collections/Cryoprecipitate_transfusion_in_trauma_patients_attenuates_hyperfibrinolysis_and_restores_normal_clot_structure_and_stability_Results_from_a_laboratory_sub-study_of_the_FEISTY_trial/6218372 and one more link, https://springernature.figshare.com/collections/Cryoprecipitate_transfusion_in_trauma_patients_attenuates_hyperfibrinolysis_and_restores_normal_clot_structure_and_stability_Results_from_a_laboratory_sub-study_of_the_FEISTY_trial/6218372/1 (show fewer)
Dataset

Cite this

Morrow, G. B., Feller, T., McQuilten, Z., Wake, E., Ariëns, R. A. S., Winearls, J., Mutch, N. J., Laffan, M. A., & Curry, N. (2022). Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial. Critical Care, 26(1), [290]. https://doi.org/10.1186/s13054-022-04167-x

Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability : Results from a laboratory sub-study of the FEISTY trial. / Morrow, Gael B. (Corresponding Author); Feller, Timea; McQuilten, Zoe et al.

In: Critical Care, Vol. 26, No. 1, 290, 26.09.2022.

Research output: Contribution to journal › Article › peer-review

Morrow, GB, Feller, T, McQuilten, Z, Wake, E, Ariëns, RAS, Winearls, J, Mutch, NJ, Laffan, MA & Curry, N 2022, 'Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial', Critical Care, vol. 26, no. 1, 290. https://doi.org/10.1186/s13054-022-04167-x

@article{860799611b3f4f0cbba9f75db039d2eb,

title = "Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial",

abstract = "Fibrinogen is the first coagulation protein to reach critical levels during traumatic haemorrhage. This laboratory study compares paired plasma samples pre- and post-fibrinogen replacement from the Fibrinogen Early In Severe Trauma studY (FEISTY; NCT02745041). FEISTY is the first randomised controlled trial to compare the time to administration of cryoprecipitate (cryo) and fibrinogen concentrate (Fg-C; Riastap) in trauma patients. This study will determine differences in clot strength and fibrinolytic stability within individuals and between treatment arms.",

keywords = "Fibrinogen, cryoprecipitate, clot structure, Trauma coagulopathy, fibrinolysis",

author = "Morrow, {Gael B.} and Timea Feller and Zoe McQuilten and Elizabeth Wake and Ari{\"e}ns, {Robert A. S.} and James Winearls and Mutch, {Nicola J.} and Laffan, {Mike A.} and Nicola Curry",

note = "Acknowledgements We acknowledge the Aberdeen Microscopy and Histology Core Facility and thank Judith de Vries for her guidance in analysing the confocal images. We thank Megan Simpson for measuring PAI-1 and uPA antigen levels in the fibrinogen preparations. We thank all of the FEISTY research staff who collected and processed the patient samples. Funding This work was supported by research grants from CSL Behring and Tenovus Scotland.",

year = "2022",

month = sep,

day = "26",

doi = "10.1186/s13054-022-04167-x",

language = "English",

volume = "26",

journal = "Critical Care",

issn = "1364-8535",

publisher = "Springer Science + Business Media",

number = "1",

}

TY - JOUR

T1 - Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability

T2 - Results from a laboratory sub-study of the FEISTY trial

AU - Morrow, Gael B.

AU - Feller, Timea

AU - McQuilten, Zoe

AU - Wake, Elizabeth

AU - Ariëns, Robert A. S.

AU - Winearls, James

AU - Mutch, Nicola J.

AU - Laffan, Mike A.

AU - Curry, Nicola

N1 - Acknowledgements We acknowledge the Aberdeen Microscopy and Histology Core Facility and thank Judith de Vries for her guidance in analysing the confocal images. We thank Megan Simpson for measuring PAI-1 and uPA antigen levels in the fibrinogen preparations. We thank all of the FEISTY research staff who collected and processed the patient samples. Funding This work was supported by research grants from CSL Behring and Tenovus Scotland.

PY - 2022/9/26

Y1 - 2022/9/26

N2 - Fibrinogen is the first coagulation protein to reach critical levels during traumatic haemorrhage. This laboratory study compares paired plasma samples pre- and post-fibrinogen replacement from the Fibrinogen Early In Severe Trauma studY (FEISTY; NCT02745041). FEISTY is the first randomised controlled trial to compare the time to administration of cryoprecipitate (cryo) and fibrinogen concentrate (Fg-C; Riastap) in trauma patients. This study will determine differences in clot strength and fibrinolytic stability within individuals and between treatment arms.

AB - Fibrinogen is the first coagulation protein to reach critical levels during traumatic haemorrhage. This laboratory study compares paired plasma samples pre- and post-fibrinogen replacement from the Fibrinogen Early In Severe Trauma studY (FEISTY; NCT02745041). FEISTY is the first randomised controlled trial to compare the time to administration of cryoprecipitate (cryo) and fibrinogen concentrate (Fg-C; Riastap) in trauma patients. This study will determine differences in clot strength and fibrinolytic stability within individuals and between treatment arms.

KW - Fibrinogen

KW - cryoprecipitate

KW - clot structure

KW - Trauma coagulopathy

KW - fibrinolysis

U2 - 10.1186/s13054-022-04167-x

DO - 10.1186/s13054-022-04167-x

M3 - Article

C2 - 36163263

VL - 26

JO - Critical Care

JF - Critical Care

SN - 1364-8535

IS - 1

M1 - 290

ER -

Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial

Abstract

Keywords

Access to Document

Fingerprint

Datasets

Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial

Cite this